...
首页> 外文期刊>Revista de la Sociedad Espanola del Dolor >Efectividad y seguridad de la viscosuplementación con dosis única de ácido hialurónico estabilizado de origen no animal (NASHA) para el tratamiento del dolor secundario a gonartrosis
【24h】

Efectividad y seguridad de la viscosuplementación con dosis única de ácido hialurónico estabilizado de origen no animal (NASHA) para el tratamiento del dolor secundario a gonartrosis

机译:单剂量非动物来源稳定化透明质酸(NASHA)黏膜补充剂治疗淋病性继发性疼痛的有效性和安全性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: to evaluate the effectiveness and safety of single-dose injection of stabilized hyaluronic acid of non-animal origin (NASHA) for the treatment of pain related to knee osteoarthritis. Material and methods: we included a total of 37 patients with previously diagnosed gonarthritis by the Orthopedist/Rheumatologist in which conservative treatment has failed and/or who are not candidates for surgery. They carried out a single-dose injection of non-animal stabilized hyaluronic acid (Durolane?). We collected demographic data, adverse effects and pain intensity (assessed by verbal numeric scale) and scores on the questionnaires Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Barthel -baseline, at 2 weeks, at 3 months and 6 months of infiltration-. It has been considered effective a decrease ≥ 30% for more than 3 months at baseline scores. Results: patients are predominantly female (83.8%) with a mean age of 72.8 years (standard deviation = -S-8.4) and mean body mass index (BMI) 31.9 (S = 6.9). The left knee is infiltrated in 51.7%, 41.4% right and bilateral in 6.9% of patients. Adverse effects have occurred as well tolerated arthralgia 11.1% of patients. Based on the results, the infiltration with single dose of stabilized hyaluronic acid of non-animal origin for osteoarthritic source gonalgia caused a statistically significant reduction in pain intensity (numerical verbal scale and WOMAC) and functional capacity (WOMAC) at all measured intervals. There has been a ≥ 30% reduction in pain intensity in 54% (value that matches the reduction in WOMAC pain score) in 62.1% stiffness and functional capacity in 48.6% of patients. Conclusion: in our patients, intra-articular viscosupplementation single dose of stabilized hyaluronic acid of non-animal origin (NASHA, Durolane?) for the treatment of pain related to gonarthritis has been effective and safe and is a weapon for the management of pain and disability gonarthritis generated.
机译:目的:评估单剂量非动物源稳定化透明质酸(NASHA)注射液治疗膝骨关节炎相关疼痛的有效性和安全性。材料和方法:我们总共纳入了37位先前由骨科医生/风湿病专家诊断为淋病的患者,其中保守治疗失败和/或不适合手术。他们进行了非动物稳定的透明质酸(Durolane?)的单剂量注射。在第2周,第3个月和第6个月浸润时,我们收集了人口统计学数据,不良反应和疼痛强度(通过口头数字量表进行了评估),并在西安大略和麦克马斯特大学骨关节炎指数(WOMAC)和Barthel-基线问卷上进行了评分。 。在基线评分时,超过3个月的有效减少≥30%被认为是有效的。结果:患者主要是女性(83.8%),平均年龄为72.8岁(标准差= -S-8.4),平均体重指数(BMI)为31.9(S = 6.9)。左膝浸润的患者占51.7%,右侧浸润的占41.4%,双侧浸润的占6.9%。耐受不良的关节痛发生率达11.1%。根据结果​​,在所有测量的时间间隔内,单剂量非动物来源的稳定化透明质酸对骨关节炎源性淋巴瘤的浸润均导致疼痛强度(数字语言量表和WOMAC)和功能能力(WOMAC)的统计学显着降低。在48.6%的患者中,疼痛强度降低了≥30%,降低了54%(与WOMAC疼痛评分降低的值相符),而刚度和功能能力降低了62.1%。结论:在我们的患者中,非动物来源的稳定的透明质酸关节腔内单剂量透明质酸(NASHA,Durolane?)用于治疗与性关节炎相关的疼痛是有效且安全的,并且是治疗疼痛和疼痛的武器。残疾性关节炎。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号